Patent application number | Description | Published |
20100111912 | COMPOSITIONS AND METHODS FOR TARGETED ABLATION OF MUTATIONAL ESCAPE OF TARGETED THERAPIES FOR CANCER - Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents. | 05-06-2010 |
20110256098 | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION - Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes. | 10-20-2011 |
20130121964 | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy - Disclosed are improved methods for treating an infectious disease with yeast-based immunotherapy, including viral disease, such as disease resulting from hepatitis virus infection, using a pharmacogenomic and response-guided approach based on IL28B genotype of the individual. | 05-16-2013 |
20140004135 | YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS | 01-02-2014 |
20140065182 | YEAST-BASED THERAPEUTIC FOR CHRONIC HEPATITIS B INFECTION - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 03-06-2014 |
20140072590 | Compositions and Methods for the Treatment or Prevention of Human Adenovirus-36 Infection - Disclosed are fusion proteins, recombinant nucleic acid molecules, and therapeutic compositions, including yeast-based immunotherapy compositions, for use in the diagnosis, prevention and treatment of adenovirus-36 (Ad-36) infection and sequela thereof. | 03-13-2014 |
20140234375 | Compositions and Methods for Eliciting an Immune Response to Escape Mutants of Targeted Therapies - Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response. | 08-21-2014 |
Patent application number | Description | Published |
20100033565 | Infrared Defect Detection System and Method for the Evaluation of Powdermetallic Compacts - A pulsed thermography defect detection apparatus including active and passive infrared (IR) thermography for non-destructive testing (NDT) of powdermetallic (P/M) components for on-line and off-line inspection. | 02-11-2010 |
20130199680 | Aluminum Die Casting Alloy - Aluminum die casting alloy comprising 2 to 6% by weight nickel, 0.1 to 0.4% by weight zirconium, 0.1 to 0.4% by weight vanadium, optionally up to 5% by weight manganese, optionally up to 2% by weight iron, optionally up to 1% by weight titanium, optionally total max. 5% by weight transition elements including scandium, lanthanum, yttrium, hafnium, niobium, tantalum, chromium and/or molybdenum, and aluminum as the remainder with further elements and impurities due to production total max. 1% by weight. | 08-08-2013 |
20130302226 | METHOD AND APPARATUS FOR RECYCLING LITHIUM-ION BATTERIES - Cathode material from exhausted lithium ion batteries are dissolved in a solution for extracting the useful elements Co (cobalt), Ni (nickel), Mn (manganese), Li (lithium), and Fe (iron) to produce active cathode materials for new batteries. The solution includes compounds of desirable materials such as cobalt, nickel and manganese dissolved as compounds from the exhausted cathode material of spent cells. Depending on a desired proportion, or ratio, of the desired materials, raw materials are added to the solution to achieve the desired ratio of the commingled compounds for the recycled cathode material for new cells. The desired materials precipitate out of solution without extensive heating or separation of the desired materials into individual compounds or elements. The resulting active cathode material has the predetermined ratio for use in new cells, and avoids high heat typically required to separate the useful elements because the desired materials remain commingled in solution. | 11-14-2013 |
20130323611 | HIGH ENERGY DENSITY FLOW BATTERIES - A nickel/zinc (Ni/Zn) flow battery employs a solid suspension charge material to maintain high charge density via stability of a suspension including a binder, conductive carbon and an electrolyte. Zinc oxide (ZnO) is employed as the anodic (anode) charge material and nickel hydroxide (Ni(OH) | 12-05-2013 |